Bright Minds Biosciences announces data from preclinical testing of BMB-201

Bright Minds Biosciences announced data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening program. Preclinical pain models included plantar incision and L5/L6 nerve ligation rat models, where the drug candidate was tested along with morphine and gabapentin as positive controls. Key Highlights from the Study: In nerve ligation pain models, BMB-201 had similar efficacy to morphine, demonstrating superior reductions in mechanical allodynia and pain-related behaviors. Female rodents experienced a marked improvement in both pain relief and guarding behavior, with higher doses producing a significant therapeutic effect. BMB-201’s efficacy suggests that it may provide better pain relief than traditional opioid treatments, without the associated risks of dependency and side effects. Next Steps: With these preclinical results, Bright Minds plans to advance BMB-201 into clinical trials to further evaluate its safety and efficacy in human subjects. The company aims to position BMB-201 as a non-opioid alternative for neuropathic pain relief, addressing a significant unmet need in the pain management landscape. BMB-201 constitutes a novel MoA for the modulation of pain perception. This data has been presented at Society for Neuroscience’s annual meeting at the NIH Satellite Forum.